1
2
3
4
5
Now Trending SPY AAPL BP DIA QQQQ GS APA JPM BHP AIG
If you think ALTH is headed higher click
higher
If you think ALTH is headed lower click
lower
Aroon
MGA
VMW
APD
IHS
SLG
PXD
MUR
BG
ACE
EIS
MMP
KSS
AMT
Bullish
MICC
FFIV
GENZ
NDSN
CHRW
ADVS
ORLY
DLTR
HANS
LIFE
QCOM
ADTN
VRSN
Aroon
CMP
BBG
HRC
DBD
PNG
CNC
TII
AHD
SCI
CTC
Bearish
DMND
IART
ACOM
PSSI
ABAX
MXWL
QCOR
SWIR
SEAC
ARNA
ALTH

Premium Advice

ALTH

Allos Therapeutics, Inc.

Recent Community Picks
FCX up
AAPL up
ISF up
UAUA up
TZA up
SPY up
CF up
MMYT up
ORCL up
GS up
SHLD up
JPM up
BCON up
PFE up
FSLR up
NFLX up

Last Trade: 4.08
%Change: +2.26%
Volume Analysis
Average Volume: 1072430
Half Hour Run Rate: 82494
1 Minute Run Rate: 2749
Run Rate Based: 1072110
Current Volume: 610008
ALTH is currently neutral.
P/E: N/A
Market Cap: 429.8M
52 Week High: 8.79
52 Week Low: 3.58
Next Year EPS: -0.47
Similar Stocks to ALTH
MYL HSP CTIC GENZ CEPH BIIB
Twitter Updates: ALTH
shiladityam shiladityam
Evn @ d peak of power, Russia cudn't go aggressive on it. Alaska became #USA's Siberia- untapped, unexplored, mineral-rich... #StockMarket
rpReply! RTRetweet!

theinvestingpro theinvestingpro
Top stories of the day ? China Stock Market ? Sept. 6 http://bit.ly/cFVwwh #stockmarket
rpReply! RTRetweet!

damnhotstocks damnhotstocks
Find info for Stockmarket #Stockmarket at http://bit.ly/bOLWZ3
rpReply! RTRetweet!

wallstreet_guru wallstreet_guru
World Record Trader Turned $10k into over $40 million dollars http://bit.ly/bOkVAC #Stocks #StockMarket #StockPicks http://lx.im/6aZ6

ALTH - Allos Therapeutics, Inc.

Chart PatternChart Pattern
Allos Therapeutics, Inc. is a biopharmaceutical company that is focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company's lead product candidate, pralatrexate (PDX) an antifolate, is in Phase II trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also investigating PDX in patients with non-small cell lung cancer and a range of other lymphoma sub-types. The Company's other product candidate is RH1, a targeted chemotherapeutic agent, which is in a Phase I trial in patients with advanced solid tumors or non-Hodgkin's Lymphoma. In February 2009, the Company announced the final results from PROPEL, its pivotal Phase II trial of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This trial was conducted under an agreement reached with the United States Food and Drug Administration (FDA) under its special protocol assessment (SPA) process.

The Aroon technical indicator is quite new and was developed by Tushar Chande in 1995. Similar to the MACD, it is used for identifying trends in an underlying security and tries to determine what the chances are that the trends will reverse. The indicator is made up of two lines: The first line is called the Aroon Up, which measures the strength of the uptrend. The second line is called the Aroon Down, and it conversely measures the strength of a downtrend. The Aroon indicator reports the time it is taking for the price to reach the highest or lowest points over a given period of time, each reported as a percentage of total time. The Aroon up as well as the Aroon Down fluctuate between zero and 100, and values close to 100 indicate a very strong trend, while zero indicates a weak trend. The main assumption underlying this indicator is that a stock's price will close at record highs in an uptrend, and record lows in a downtrend.